These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21868344)

  • 1. [Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer].
    Feng Y; Zhou HX; Li JH; Li ZY; Cheng WG; Jin ML; He L
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Aug; 31(8):1448-51. PubMed ID: 21868344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase Y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma.
    Fan DM; Shi HR
    Int J Mol Sci; 2011; 12(12):8489-501. PubMed ID: 22272086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal adhesion kinase (FAK) immunocytochemical expression in breast ductal invasive carcinoma (DIC): correlation with clinicopathological parameters and tumor proliferative capacity.
    Theocharis SE; Klijanienko JT; Padoy E; Athanassiou S; Sastre-Garau XX
    Med Sci Monit; 2009 Aug; 15(8):BR221-6. PubMed ID: 19644410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome.
    Schmitz KJ; Grabellus F; Callies R; Otterbach F; Wohlschlaeger J; Levkau B; Kimmig R; Schmid KW; Baba HA
    Breast Cancer Res; 2005; 7(2):R194-203. PubMed ID: 15743500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.
    Ravi A; Kaushik S; Ravichandran A; Pan CQ; Low BC
    J Biol Chem; 2015 Feb; 290(7):4149-62. PubMed ID: 25525271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
    Li G; Du X; Vass WC; Papageorge AG; Lowy DR; Qian X
    Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17129-34. PubMed ID: 21969587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Focal adhesion kinase expression and angiogenesis in breast carcinoma].
    Huang YD; Zhang S
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep; 27(9):1370-3. PubMed ID: 17884781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes.
    Cance WG; Harris JE; Iacocca MV; Roche E; Yang X; Chang J; Simkins S; Xu L
    Clin Cancer Res; 2000 Jun; 6(6):2417-23. PubMed ID: 10873094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynein light chain 1 contributes to cell cycle progression by increasing cyclin-dependent kinase 2 activity in estrogen-stimulated cells.
    den Hollander P; Kumar R
    Cancer Res; 2006 Jun; 66(11):5941-9. PubMed ID: 16740735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
    Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
    Behmoaram E; Bijian K; Jie S; Xu Y; Darnel A; Bismar TA; Alaoui-Jamali MA
    Am J Pathol; 2008 Nov; 173(5):1540-50. PubMed ID: 18832579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression and significance of phosphorylated Girdin in breast cancer].
    Xu Y; Fu L; Gu F; Ma YJ
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):205-9. PubMed ID: 22780975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer.
    Gökmen-Polar Y; True JD; Vieth E; Gu Y; Gu X; Qi GD; Mosley AL; Badve SS
    PLoS One; 2018; 13(10):e0204658. PubMed ID: 30278072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
    Yang JQ; Chen L; Xing TY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of DCC protein in female breast cancer.
    Koren R; Dekel Y; Sherman E; Weissman Y; Dreznik Z; Klein B; Gal R
    Breast Cancer Res Treat; 2003 Jul; 80(2):215-20. PubMed ID: 12908825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Abnormal expression of RSK-4 and its clinical significance in breast cancer].
    Liu JL; Yang HW; Chen ZS; Jiang Y
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):452-6. PubMed ID: 21875487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
    Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.